Skip to content
OpenCapital
Get started

LivaNova LIVN Free cash flow

Free cash flow at other companies

Abbott logo
AbbottABT
$916M-1.8%
Medtronic logo
MedtronicMDT
$2.09B+0.8%
ResMed logo
ResMedRMD
$520.48M-6.7%
Boston Scientific logo
Boston ScientificBSX
$171M-51.7%
Stryker logo
StrykerSYK
$415M+227%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$24.67M+26.5%

Other financials

Income statement

See full
Revenue$362.3M+14.3%
Gross profit$243.7M+12.7%
Operating income$41.5M-14.7%
Net income$22.3M+107%
EPS (diluted)$0.40+107%

Balance sheet

See full
Cash & equivalents$539.7M-26.9%
Total debt$340.9M-49.7%
Total equity$1.2B+17.1%
Total assets$2.5B-1.7%

Cash flow

See full
Operating cash flow$15.2M-36.5%
CapEx$14.3M+32.4%

Valuation

See full
Market cap$4.31B+62.8%
Enterprise value$4.11B+58.0%
P/S3×+0.9×

Profitability

See full
Gross margin67.5%-0.5pp
Operating margin13.4%+0.8pp
Net margin-16.1%-18.0pp
FCF margin11.2%-0.2pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.4×
Current ratio1.3×-0.2×

Where this comes from

Calculated from LivaNova’s reported figures.

$15.2Mnet cash from operating−$14.3Mcapital expenditures=$926K

The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LivaNova's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LivaNova's free cash flow?
LivaNova (LIVN) reported free cash flow of $926K in Q1 2026.
How has LivaNova's free cash flow changed year-over-year?
LivaNova's free cash flow decreased by 93.0% year-over-year, from $13.18M to $926K.
What is the long-term trend for LivaNova's free cash flow?
Over 3 years (2021 to 2025), LivaNova's free cash flow has grown at a 31.0% compound annual growth rate (CAGR), from $77.07M to $173.29M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.